TRANCYST
Translational research (training) in Polycystic Kidney Disease
| Coordinatore | ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 2˙763˙732 € |
| EC contributo | 2˙763˙732 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2012-ITN |
| Funding Scheme | MC-ITN |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-12-01 - 2016-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | coordinator | 757˙933.50 |
| 2 |
THE UNIVERSITY OF SHEFFIELD
Organization address
address: FIRTH COURT WESTERN BANK contact info |
UK (SHEFFIELD) | participant | 575˙613.25 |
| 3 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 497˙673.88 |
| 4 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 258˙148.66 |
| 5 |
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
Organization address
address: Via Giuseppe La Masa 19 contact info |
IT (MILANO) | participant | 243˙037.95 |
| 6 |
MOSAIQUES DIAGNOSTICS GMBH
Organization address
address: Mellendorfer Strasse 7-9 contact info |
DE (HANNOVER) | participant | 224˙268.88 |
| 7 |
ServiceXS BV
Organization address
address: Plesmanlaan 1.d contact info |
NL (Leiden) | participant | 207˙056.73 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Autosomal Dominant Polycystic Kidney Disease (ADPKD) is an inherited kidney disorder with a prevalence of more than 1:1000, characterized by the development of renal cysts, slowly progressing towards end-stage renal disease. ADPKD is often associated with extra-renal complications, which can be devastating. Current therapy is directed towards limiting the morbidity and mortality from these complications, whereas effective specific treatments targeting the renal cystic disease are missing. Translational research using innovative approaches from molecular genetics, basic sciences to clinical applications are necessary to unravel the disease mechanism and to develop interventions, monitoring of cystic renal disease progression and to slow down renal cystic disease.
In this context, the aim of TranCYST is to offer a multidisciplinary research training program to young researchers for the identification, characterization, and development of novel treatments in ADPKD, to prepare them to become leading scientists who are able to translate fundamental research questions to the clinic and vice versa,'